A5057847754- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- CRISPR and Genetic Engineering
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
University of Michigan–Ann Arbor
2024
BioNTech (United States)
2020
The maintenance of antigen-specific CD8
T cells use highly diverse receptors (TCRs) to identify tumor presenting neoantigens arising from genetic mutations and establish anti-tumor activity. Immunotherapy harnessing neoantigen-specific target tumors has emerged as a promising clinical approach. To assess whether comprehensive peripheral mononuclear blood cell analysis predicts responses personalized neoantigen cancer vaccine combined with anti-PD-1 therapy, we characterize the TCR repertoires B frequencies in 21 patients...
<h3>Background</h3> Acute myeloid leukemia (AML) is the most common form of in adults. However, clinical outcome for high-risk patients remains poor, highlighting urgent need development new therapeutic strategies [1]. Chimeric antigen receptor (CAR) T cell therapy holds promise as an immunotherapeutic strategy and targeting C-type lectin-like molecule-1 (CLL-1, CD371) represents attractive approach, CLL-1 highly expressed on AML blasts leukemic stem cells Here, we present preclinical data...